EN
Statement
Statement
We have recently noticed that some companies and individuals illegally forged and used authorization documents from Sinovac Biotech Co., Ltd. (“Sinovac Beijing”) or Sinovac Life Sciences Co., Ltd. (“Sinovac Life Sciences”), two subsidiaries of Sinovac Biotech Ltd. (“Sinovac”), to hold out that Sinovac Beijing or Sinovac Life Sciences has authorized them to act as the distributor to distribute the Covid-19 vaccine CoronaVac® and the other vaccine products in the markets outside China.
We wish to clarify that:
(i) the Covid-19 vaccine CoronaVac® is developed, manufactured and distributed by Sinovac Life Sciences;
(ii) Sinovac Beijing is not engaged in distribution of the Covid-19 vaccine CoronaVac® outside China; and
(ii) neither Sinovac nor any of its subsidiaries has ever signed any authorization letter or similar documents for any company or individual within China to authorize them to distribute the Covid-19 vaccine CoronaVac® outside China.
We hereby reiterate that, without signing written contracts with us, no entity or individual may hold out that it is or is authorized to be engaged in sale, distribution or other marketing or promotion activities related to any of Sinovac’s vaccine products.
Concerning the illegal activities of document forging and fraudulence as mentioned, we reserve all the rights to take actions, including legal actions, to seek remedies and pursue liabilities.
Sinovac Biotech Ltd.
28 January 2021
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com